Nifty 17053.95 (0.16%)
Sensex 57260.58 (0.27%)
Nifty Bank 35976.45 (-0.14%)
Nifty IT 34870.75 (0.76%)
Nifty Financial Services 17629.95 (0.09%)
Adani Ports 702.60 (-2.03%)
Asian Paints 3144.30 (0.04%)
Axis Bank 651.10 (-1.61%)
B P C L 367.45 (-2.49%)
Bajaj Auto 3298.20 (-1.09%)
Bajaj Finance 6905.75 (1.45%)
Bajaj Finserv 16890.40 (1.25%)
Bharti Airtel 739.35 (0.08%)
Britannia Inds. 3528.60 (-0.75%)
Cipla 965.00 (-0.18%)
Coal India 154.25 (-1.06%)
Divis Lab. 4921.35 (-0.33%)
Dr Reddys Labs 4697.60 (-1.12%)
Eicher Motors 2413.40 (-0.84%)
Grasim Inds 1683.95 (-0.36%)
H D F C 2713.80 (-1.02%)
HCL Technologies 1133.15 (2.08%)
HDFC Bank 1501.25 (0.76%)
HDFC Life Insur. 683.65 (1.94%)
Hero Motocorp 2490.80 (-1.53%)
Hind. Unilever 2329.40 (-0.24%)
Hindalco Inds. 420.15 (0.76%)
I O C L 118.80 (-1.78%)
ICICI Bank 718.40 (-0.53%)
IndusInd Bank 895.45 (-0.70%)
Infosys 1696.35 (0.28%)
ITC 221.50 (-1.12%)
JSW Steel 625.60 (-0.49%)
Kotak Mah. Bank 2019.60 (2.82%)
Larsen & Toubro 1767.25 (-0.61%)
M & M 850.80 (-0.35%)
Maruti Suzuki 7149.50 (-0.29%)
Nestle India 19000.40 (-1.15%)
NTPC 126.50 (-1.82%)
O N G C 144.10 (-2.04%)
Power Grid Corpn 200.25 (-0.87%)
Reliance Industr 2441.50 (1.20%)
SBI Life Insuran 1136.25 (0.52%)
Shree Cement 25540.05 (-1.56%)
St Bk of India 465.10 (-1.15%)
Sun Pharma.Inds. 751.05 (-2.12%)
Tata Consumer 766.00 (-0.09%)
Tata Motors 461.45 (0.27%)
Tata Steel 1114.75 (0.22%)
TCS 3502.00 (1.60%)
Tech Mahindra 1536.65 (0.61%)
Titan Company 2324.20 (1.39%)
UltraTech Cem. 7388.25 (-0.09%)
UPL 689.35 (-2.05%)
Wipro 630.60 (1.47%)
INFY

Bal Pharma Ltd.

₹100.
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Bal Pharma

  • Master Rating:
  • Bal Pharma has an operating revenue of Rs. 271.84 Cr. on a trailing 12-month basis. An annual revenue growth of 46% is outstanding, Pre-tax margin of 2% needs improvement, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 45%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Bal Pharma Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Bal Pharma Ltd Synopsis

NSE-Medical-Diversified

Bal Pharma Ltd belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 249.31 Cr. and Equity Capital is Rs. 14.82 Cr. for the Year ended 31/03/2021. Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368.
  • Market Cap

    INR 148.22 Cr

  • Sales

    INR 270.59 Cr

  • Shares in Float

    0.79 Cr

  • No of Funds

    1 K

  • Yield

    1%

  • Book Value

    1.87

  • U/D Vol Ratio

    1.4

  • LTDebt/Equity

    30%

  • Alpha

    0.18

  • Beta

    1.03

Bal Pharma Ltd Ownership
Bal Pharma Ltd Management

Bal Pharma Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 79.317665.944876.859572.23466.5866
Fixed Assets Annual Cr 52.651556.241156.997758.495561.4263
Total Non Current Assets Annual Cr 68.339966.840969.786169.616368.4927
Total Current Assets Annual Cr 193.1997172.4723187.3662181.4795150.3517
Total Assets Annual Cr 261.5396239.3132257.1523251.0958218.8444
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 46.5354.23150.96846.983
ROE Annual % -13.498.798.227.98
ROCE Annual % 3.3614.8414.9117.66
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 11.636.0710.3311.5710.4

Bal Pharma Ltd Technicals

EMA & SMA

CURRENT PRICE

100 (-0.25)

    • Bullish Moving Averages 13
    • Bearish Moving Averages 3

EMA

  • 20 Day

    98.39

  • 50 Day

    99.02

  • 100 Day

    96.67

  • 200 Day

    89.31

Bal Pharma Ltd Resistance and support

101.79 PIVOT

  • First Resistance

    106.47

  • Second Resistance

    112.69

  • Third Resistance

    117.37

  • First Support

    95.57

  • Second Support

    90.89

  • Third Support

    84.67

  • RSI

    52.86

  • MFI

    59.29

  • MACD

    -0.01

  • MACD signal line

    -0.76

Bal Pharma Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 134,444 6,179,046 45.96%
Week 326,706 17,962,285 54.98%
1 Month 107,945 6,188,499 57.33%
6 Month 97,432 5,765,057 59.17%

Bal Pharma Ltd Price change analysis

3.9

Over 1 month

Low High
90.8 109.7

6.7

Over 3 month

Low High
90.8 114.4

-8.75

Over 6 months

Low High
87.65 114.4

44.25

Over Year

Low High
49.55 137.95

Similar Stocks

News

BAL PHARMA LTD. - 524824 - Disclosure Of Related Party Trans

We are submitting to the exchange the disclosure of related party transactions on consolidated basis for the half year ended 30/09/2021 draw Read More

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30

We are submitting to the exchange newspaper advertisements of Notice issued to the shareholders of the Company regarding transfer of shares Read More

Bal Pharma Ltd - 524824 - Disclosures under Reg. 29(2) of SE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More

Bal Pharma Consolidated September 2021 Net Sales at Rs 67.17

NULL Read More

Buzzing Stocks: Bal Pharma, Vedanta and other stocks in news

Stocks In News: Check out the companies making the biggest headlines before the opening bell. Read More

Blogs

FAQs